Stephen Mccluski - Sep 13, 2023 Form 4 Insider Report for ImmunoGen, Inc. (IMGN)

Role
Director
Signature
/s/ Renee Lentini, Attorney-in-Fact
Stock symbol
IMGN
Transactions as of
Sep 13, 2023
Transactions value $
-$13,500
Form type
4
Date filed
9/14/2023, 05:30 PM
Previous filing
Aug 17, 2023
Next filing
Feb 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGN Common Stock Options Exercise $147K +10K $14.70 10K Sep 13, 2023 Direct F1
transaction IMGN Common Stock Options Exercise -$161K -10K -100% $16.05 0 Sep 13, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -10K -100% $0.00* 0 Sep 13, 2023 Common Stock 10K $14.70 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on June 14, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.90 to $16.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F3 This option was granted on 11/12/2013 and is fully vested as of the transaction date.